membranes from rats treated with 17a-ethinyl estradiol, and liver membranes from normal rabbits. The apo E-D from six of the nine patients with F. Dys. showed binding affinities for LDL receptors that were reduced by >98% in all receptor assays (group 1 patients). All of these group 1 patients were unequivocally of phenotype apo E-D/D by the criterion ofisoelectric focussing. The apo E from the three other F. Dys. patients showed a near normal binding ability in all four of the receptor assays (group 2 patients). One of these group 2 patients appeared to have the apo E-D/D phenotype by isoelectric focussing. In the other two patients in group 2, apo E-D was the predominant protein (phenotype, apo E-D/D), but traces of protein in the region corresponding to normal apo E (apo E-N) were also present. The difference between group 1 and group 2 patients was also apparent when the apo E was iodinated and tested directly for binding to liver membranes from rats treated with 17a-ethinyl estradiol. The 125I-labeled apo E from a group 2 patient, but not a group 1 patient, showed enhanced uptake when perfused through the liver of an estradiol-treated rate, indicating that the receptor binding ability of apo E correlated with uptake in the intact liver.
The current studies allow the subdivision ofpatients with F. Dys. into two groups. In group 1, the elevated plasma level of remnants appears to be due to a diminished receptor binding activity ofthe abnormal pro-
INTRODUCTION
In familial dysbetalipoproteinemia (F. Dys.)1, also called familial type 3 hyperlipoproteinemia, abnormal very low density lipoproteins (VLDL) and intermediate density lipoproteins accumulate in plasma, producing hypercholesterolemia and hypertriglyceridemia (1, 2) . In comparison with VLDL from normal subjects, the VLDL particles from patients with F. Dys. are enriched in cholesteryl esters relative to triglyceride and exhibit ,-mobility, rather than pre-,8 mobility, on electrophoresis. These "'7-VLDL" particles are believed to be remnants derived from the partial catabolism of the triglyceride-rich lipoproteins, chylomicrons and VLDL. In animals, and probably in man, such remnant lipoproteins are rapidly removed from the circulation by means of receptor-mediated endocytosis in the liver. As a result, in normal subjects only small amounts of remnant lipoproteins are found in the circulation (1) .
Studies in rats, dogs, and rabbits have shown that the rapid hepatic uptake ofremnants is due to the binding of the lipoproteins to receptors on the hepatocyte surface (3) . These hepatic receptors resemble the low density lipoprotein (LDL) receptors that have been characterized in extrahepatic cells, such as cultured human fibroblasts and the adrenal cortex of various animal species. The hepatic and extrahepatic receptors share the following properties: (a) they bind apoprotein (apo) E with higher affinity than apo B; (b) binding of apo B and E is dependent on Ca++ and is inhibited by EDTA; and (c) the receptors are subject to metabolic regulation by a variety of hormonal, nutritional, and pharmacologic factors (3) (4) (5) (6) (7) (8) (9) . Although remnant lipoproteins contain both apo B and apo E, it is generally believed that the apo E component confers high affinity for the hepatic receptors (1, 3, 6) .
Genetic studies in humans by Utermann (10) (11) (12) and by Zannis and Breslow (13, 14) have shown that apo E is specified by a polymorphic genetic locus with three alleles, here designated apoEn, E4, andEd.2 These three alleles give rise to six genotypes: apo En/En, E4/E4, Ed/Ed, En/E4, En/Ed, and E4/Ed. The proteins specified by each allele are called isoforms. suggests that the apo E isoforms specified by alleles E" and E4 are functionally normal, whereas the apo E specified by allele Ed may be functionally abnormal (1). The protein specified by the Ed allele has one less positive charge than the protein specified by the E" allele and two less positive charges than the protein specified by the E4 allele (10) (11) (12) (13) (14) . Approximately 1% of individuals in the population are homozygous for the Ed allele (10) (11) (12) (13) (14) .
Virtually all patients with classic F. Dys. so far studied have been homozygous for the Ed allele (1, 11, 13) . However, most subjects who are homozygous for the Ed allele do not have elevated cholesterol or triglyceride levels. These subjects have only small amounts of ,8-VLDL in their plasma and they do not appear to have accelerated atherosclerosis or the other clinical features of F. Dys. (10) (11) (12) . For this reason Utermann has proposed that the full expression of F. Dys. requires at least two factors: (a) homozygosity for the Ed allele (i.e., genotype Ed/Ed); and (b) a triggering factor such as hypothyroidism, or the independent inheritance of another form of hyperlipoproteinemia such as familial combined hyperlipoproteinemia or familial hypercholesterolemia (11) .
Considered together, the above information raised the possibility that the accumulation of (3-VLDL in F. Dys. patients is due to a failure of apo E-D, the protein specified by the Ed allele, to bind to hepatic receptors. Evidence in favor of this hypothesis has appeared in two recent studies. First, Havel and associates isolated apo E from normal subjects and patients with F. Dys. and labeled them with 125I (15) . Complexes of the 125IJ labeled apo E with phospholipid were perfused through the livers ofrats that had been treated with 17a-trophoresis, Zannis and Breslow have proposed that isoforms ,8/-V (corresponding to E-2), /3-III (corresponding to E-3), and ,8-TI (corresponding to E-4) are-each specified by one of three alleles at a single locus and that minor isoforms, including those corresponding to E-1, occur as a result of posttranslational glycosylation of one of the three major isoforms (13, 14) . The following two lines of evidence indicate that isoforms E-2, E-3, and E-4 (Utermann nomenclature) correspond to isoforms ,8-IV, /3-III, and ,8-IT (Zannis-Breslow nomenclature).
First, when apo E was treated with neuraminidase and then subjected to one-dimensional isoelectric focusing, we observed a simplified isoform pattern that was comparable to that observed with two-dimensional electrophoresis (35) . Second, direct comparison of the one-dimensional and two-dimensional electrophoretic patterns of the same apo E preparations showed that isoforms E-2, E-3, and E-4 correspond to isoforms /8-TV, /8-ITT, and /3-TI, respectively (36) . For purposes of terminology in the current paper, the En allele specifies predominantly the E-3 or E-N isoform, the Ed allele specifies predominantly the E-2 or E-D isoform, and the E4 allele specifies predominantly the E-4 isoform. Thus, ethinyl estradiol to increase the number of hepatic lipoprotein receptors. The uptake of the 125I-labeled apo E-D was markedly reduced compared with normal 1251-labeled apo E. Second, Gregg et (4, 5) .
Lipoproteins and apoproteins
Human VLDL (d < 1.006 g/ml) and LDL (d, 1.019-1.063 g/ml) were prepared from plasma or serum of fasting subjects by ultracentrifugation (17) . Rabbit 3-VLDL (d < 1.006 g/ml) was isolated from animals fed a cholesterol-corn oil diet as previously described (9 (18) . Apo E was radiolabeled with 125I by a modification (19) (22) . Unilamellar liposomes of egg phosphatidylcholine were prepared with a French pressure cell (23) and incubated with apo E as previously described (15) . The apo E/phosphatidylcholine complexes were isolated on Bio-Gel A-0.5 m (10% agarose, Bio-Rad Laboratories, Richmond, Calif.) (15) .
Method C. Apo E was isolated by delipidation of VLDL with tetramethylurea followed by gel chromatography in 4 M guanidine as described by Weisgraber et al. (24) . Apo E was incorporated into dimyristoylphosphatidylcholine vesicles as described by Innerarity et al. (25) . The apo E/dimyristoylphosphatidylcholine complexes were isolated by ultracentrifugation (25) . (4) . Membranes (fraction sedimenting between 8,000 and 100,000 g) were prepared from the livers of male rats treated with 17a-ethinyl estradiol (4, 5) and from the livers of normal male New Zealand White rabbits (9).
Lipoprotein binding assays
Partially purified LDL receptors from solubilized bovine adrenal cortex. Binding of 1251-LDL to partially purified LDL receptors was measured by a microporous filter assay as previously described (28) . LDL receptors were solubilized from bovine adrenal cortex with octyl-(3--glucoside, partially purified by DEAE-cellulose chromatography, and precipitated with acetone in the presence of phosphatidylcholine (29) .
Uptake of '25I-Apo Elphospholipid complexes by perfused livers
The uptake of '251-apo E/phosphatidylcholine complexes was measured in the isolated perfused liver from normal rats and rats treated with 17a-ethinyl estradiol as previously described (15) . Single-pass perfusions were conducted at a rate of 12 ml/min with Krebs-Henseleit buffer/10% rat erythrocytes. At various intervals, the concentration of 1251 in the infusate and in the effluent were measured, and the difference was taken as a measure of the amount of '25I-apo E removed by the liver.
Other assays
The protein content of lipoproteins, apo E, and cell extracts was measured by the method of Lowry et al. (30) or by radioimmunoassay (31) . The distribution of isoforms of apo E in VLDL was determined by analytical isoelectric focussing on polyacrylamide gels followed by quantitative densitometric analysis. These analyses were carried out either in Marburg (11) or in San Francisco at the Cardiovascular Research Institute (31) . The presence or absence of 1-VLDL was determined by inspection of agarose electrophoretograms that were overloaded with the d < 1.006 fraction of plasma (1, 2) . The content of cholesterol and triglycerides in serum and lipoproteins was measured as described (11, 32) .
RESULTS
Each of the nine patients in the current study exhibited the classic clinical syndrome of F. Dys. (1, 2), including elevations in the total plasma cholesterol and/or triglyceride level, an elevated ratio of cholesterol to triglyceride in VLDL, and electrophoretic evidence for ,3-VLDL (Table 1) . Four of the patients had planar or tuberous xanthomas, and six had clinical signs of atherosclerosis. Isoelectric focusing of total VLDL proteins showed the presence only of the apo E-D protein in seven of the nine patients (phenotype, apo E-D/D). In another patient J.T., isoform E-D was the major protein band,2 but a faint band was also seen in the region of the gel that is normally occupied by isoform E-N (see legend to Table I ). The apo E-D protein was estimated by visual inspection to constitute -95% of the total apo E in this patient. In patient E.S., isoform E-D was also the predominant protein band. However, this patient also had a well-defined band in the isoform E-N region, which accounted for 9% of the apo E as estimated by densitometry. None of the patients had an E-4 isoform.
Control Four different assay systems were used to assess the binding activity of apo E from control and F. Dys. patients (Table II) . These included monolayers of intact human fibroblasts, solubilized receptors from bovine adrenal cortex, liver membranes from estradiol-treated rats, and liver membranes from normal rabbits. In each system we measured the ability of increasing concentrations of unlabeled apo E/phospholipid complexes to compete with 125I-lipoproteins for binding to the LDL receptor. In three systems (human fibroblasts, bovine adrenal, and rat liver), human 1251-LDL was used as the labeled ligand; in the rabbit liver membrane system rabbit 1251-f3-VLDL was used. As shown in Table II , apo E from control subjects produced 50% inhibition of 125I1 lipoprotein binding at concentrations ranging from 0.03-0.13 ,ug/ml (human fibroblasts) to 2-6 gg/ml (rabbit liver membranes).
Apo E from six of the nine F. Dys. patients was severely defective in its ability to bind to lipoprotein receptors in each of the systems tested. These patients are hereafter referred to as group 1 patients (Table II) . Patient A.G. was the most extensively studied patient in this group. Different preparations of her apo E failed to compete significantly for '25I-LDL binding at concentrations as high as 100 ug/ml in the three systems tested (human fibroblasts, bovine adrenal, and rat liver). This was true whether the apo E/phospholipid complex was prepared by method A or B. Apo E from patients B.K., A.H., S.J., I.K., and D.R. also failed to compete for the binding of 125I-LDL or 125I-f3-VLDL at concentrations 50-fold higher than those at which control apo E competed. Apo E from three group 1 patients (A.G., B.K., and I.K.) was tested in more than one receptor system and in each case the binding deficit was similar (Table II) .
The apo E from three of the F. Dys. patients (designated Group 2 patients) was distinctly different from those in group 1 (Table II) . W.McC. was the most extensively studied patient in this group. In all four assay systems, his apo E produced 50% inhibition of 125I-lipoprotein binding at concentrations similar to those at which control apo E was effective. This was true whether the apo E/phospholipid complexes were made by methods B or C. Apo E from the two other group 2 patients (E.S. and J.T.) also showed a potent, albeit slightly reduced, ability to compete for 125I-LDL binding to human fibroblasts. The concentrations of apo E required for 50% competition ranged from 0.3-1.6 ,ug/ml. .01. * In previous studies, it was concluded that the E apoprotein from one F. Dys. patient had a near normal binding activity in cultured human fibroblasts (25) . The apo E from E.S. was used in these earlier studies.
t Apo E/phospholipid complexes from the eight control subjects were prepared as follows: method A was used for three subjects; method B for one subject; method C for two subjects; and both methods A and B were used for two subjects. 100 0.5 1 2 4 6 810A.G.
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Unlabeled Apoprotein E (jag/mi) FIGURE 1 Ability of apo E/phospholipid complexes from control subjects(0, o,Ol) and F. Dys. subjects (-) (9, 33) . Unlabeled Apoprotein E (Lg/ml) FIGURE 2 Ability of apo E/phosphatidylcholine complexes from a control subject (0) for binding to rabbit liver membranes (Fig. 3) , 50% competition occurring at a concentration of 4 ,g/ml.
Apo E from two group 1 patients (B.K. and I.K.) failed to compete significantly at concentrations as high as 24 ,g/ml.
The differences in receptor binding activity of apo E from a group 1 patient and a group 2 patient were also apparent when the apoproteins were radioiodinated and incubated with liver membranes from estradioltreated rats (Fig. 4) observed when the apoprotein/phospholipid complexes were incubated with solubilized bovine adrenal receptors (data not shown).
When the same two preparations of 125I-labeled apo E used in the in vitro binding experiments shown in Fig. 4 were perfused through isolated rat livers, a similar difference in behavior between W.McC. and A.G. was observed (Fig. 5) . With both preparations of apo E, no uptake could be detected in perfusions of livers from normal rats. However, uptake of apo E from W.McC. (group 2 patient) was greatly stimulated in livers from estradiol-treated rats (Fig. 5B) , whereas no stimulation was observed with apo E from A.G. (group 1 patient) (Fig. 5A) . The uptake of apo E from W.McC. in control and estradiol-treated rats was similar to that observed with complexes of apo E from control subjects (15) .
DISCUSSION
The current results demonstrate that apo E isolated from the plasma of some, but not all, patients with clinically symptomatic F. Dys. is markedly defective in binding to LDL receptors. On the basis of this difference in binding ability, the F. Dys. patients could be divided into two groups. In group 1 patients, who comprised six of the nine patients studied, the apo E failed to compete with 125I-LDL or 1251-,8-VLDL for binding to receptors at concentrations that were 50-to 1000-fold higher than those at which control apo E showed competition. In the other three patients studied (group 2), the isolated apo E showed a near-normal ability to compete for the binding of 125I-LDL.
The differences between the apo E of group 1 and group 2 patients were apparent whether the LDL receptors were obtained from human fibroblasts, bovine adrenal, normal rabbit liver, or estradiol-treated rat liver. The findings were consistent whether the assays were performed with intact monolayers of cells, isolated membranes, or solubilized receptors. The findings were also reproducible when apo E was isolated from the same patient on repeated occasions and studied on different days. The different binding activities of the two groups were not due to differences in methods of preparation of the apo E/phospholipid complexes: similar results were obtained with each of the three methods. The failure of the apo E-D from group 1 patients to bind to receptors was not due to a failure to be incorporated into phospholipid complexes. When the complexes were re-isolated by gel filtration, similar quantitative amounts of apo E from control subjects and group 1 and 2 patients were found to be incorporated (data not shown). Moreover, by electron microscopy the apo E/phospholipid complexes (Method B) had a similar disc-like appearance (15) The difference between the group 1 and group 2 patients that was disclosed by the competition studies was borne out by direct binding studies using 125I-labeled apo E. Moreover, the lack ofbinding of 1251-apo E from a group 1 patient to isolated hepatic membranes was associated with a marked reduction in the uptake of this lipoprotein by the perfused liver of an estradioltreated rat. Conversely, the 125I-apo E from a group 2 patient, which bound to liver membranes in a relatively normal fashion, was taken up at a normal rate (15) by the perfused rat liver.
In order to integrate all of the known aspects of F. Dys., the relationship between four variables must be elucidated: (a) the genotype at the apo E locus; (b) the phenotype of the apo E protein; (c) the ability of apo E to bind to lipoprotein receptors; and (d) the level of f3-VLDL in plasma. From the present data, it is evident that these variables are related to each other in a complex manner.
The current data show a general but not absolute correlation between apo E phenotype and apo E binding activity. All of the patients in group 1 Perfusion Volume (ml)
FIGURE 5 Uptake of 1251-apo E/phosphatidylcholine complexes from two subjects with F. Dys. into livers of normal and estradiol-treated rats perfused in a single-pass system at a rate of 12 mil/min. The '251-apo E/phosphatidylcholine complexes were the same as those used in Fig. 4 All such explanations are at present speculative. Elucidation of the modulating factors will require the integration of genetic, structural, and functional binding studies of the apo E protein of the type described in the current report.
